Howlader, N, Noone, AM, Krapcho, M, et al., eds. SEER Cancer Stat Fact Sheets. Bethesda, MD: National Cancer Institute; 2014. Available at: http://seer.cancer.gov/statfacts. Accessed 30 September 2014.Google Scholar

Nelson, HD, Fu, R, Goddard, K, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the US Preventive Services Task Force Recommendation. Evidence synthesis no. 101. AHRQ publication no. 12-05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013.Google Scholar

Struewing, JP, Hartge, P, Wacholder, S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401–8.CrossRefGoogle ScholarPubMed

Antoniou, A, Pharoah, PD, Narod, S, et al. Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117–30.CrossRefGoogle ScholarPubMed

National Collaborating Centre for Cancer. Familial breast cancer. In: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Jun, 57 p. (Clinical guideline; no. 164).Google Scholar

Moyer, V, US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2014; 160(4):271–81.Google ScholarPubMed

American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009; 113(4):957–66.Google Scholar

Berry, DA, Iverson, ES Jr, Gudbjartsson, DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20:2701.CrossRefGoogle ScholarPubMed

Unger, MA, Nathanson, KL, Calzone, K, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000; 67:841–50. [PMID: 10978226]CrossRefGoogle ScholarPubMed

Eggington, JM, Bowles, KR, Moyes, K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet 2014; 86:229.CrossRefGoogle ScholarPubMed

Garcia, C, Lyon, L, Littell, RD, Powell, CB. Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations. Genet Med 2014 May 22. [Epub ahead of print PMID 24854227]CrossRefGoogle Scholar

Ziv, E, Shephard, J, Smith-Bindman, R, Kerlikowske, K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 2003; 95(7):556–8.CrossRefGoogle ScholarPubMed

Warner, E, Messersmith, H, Causer, P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148(9):671–9.CrossRefGoogle ScholarPubMed

Garcia, C, Wendt, J, Lyon, L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol 2014 Feb; 132(2):428–33.CrossRefGoogle ScholarPubMed

Isaacs, C, Peshkin, B, Schwartz, M, et al. Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res Treat 2002; 71:103–12.CrossRefGoogle ScholarPubMed

Buys, SS, Partridge, E, Black, A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011; 305(22):2295–303.CrossRefGoogle ScholarPubMed

King, MC, Wieand, S, Hale, K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286:2251.CrossRefGoogle ScholarPubMed

Nelson, HD, Smith, ME, Griffin, JC, Fu, R. Use of medications to reduce risk of primary breast cancer: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2013; 158(8)604–14.CrossRefGoogle Scholar

Iodice, S, Barile, M, Rotmensz, N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010; 46(12):2275–84.CrossRefGoogle ScholarPubMed

Rebbeck, TR, Friebel, T, Lynch, HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055–62.CrossRefGoogle ScholarPubMed

Finch, AP, Lubinski, J, Moller, P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014; 32:1547.CrossRefGoogle ScholarPubMed

Domcheck, SM, Friebel, TM, Singer, CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967.CrossRefGoogle Scholar

Kauff, ND, Domchek, SM, Friebel, TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26:1331–7.CrossRefGoogle Scholar

Rebbek, TR, Friebel, T, Wagner, T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23(31):7804–10.Google Scholar

Lodder, LN, Frets, PG, Trijsburg, RW, et al. One-year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002; 73:97–112.CrossRefGoogle ScholarPubMed

Scheuer, L, Kauff, N, Robson, M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 25:1260–8.Google Scholar

Chompret, A, Brugieres, L, Ronsin, M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000; 82:1932.Google ScholarPubMed

Olivier, M, Goldgar, DE, Sodha, N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63:6643.Google ScholarPubMed

Salovaara, R, Loukkola, A, Kristo, P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 182:193–200.Google Scholar

Giardiello, FM, Allen, JI, Axilbund, JE, et al. AGA Section Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2014; 147:502–26.CrossRefGoogle Scholar

Vasen, HFA, Watson, P, Mecklin, JP, et al. New criteria for hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116:1453–6.CrossRefGoogle Scholar

Umar, A, Boland, CR, Terdiman, JP, et al. Revised Bethesda Guidelines for hereditary polyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261–8.Google Scholar

Dinh, TA, Rosner, BI, Atwood, JK, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 2010; 4:9–22.CrossRefGoogle ScholarPubMed

Dove-Edwin, I, Sasieni, P, Adams, J, et al. Prevention of colorectal cancer by colonoscopy surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005; 331:1047.CrossRefGoogle ScholarPubMed

Schmeler, KM, Lynch, HT, Chen, LM, et al. Prophylactic surgery to reduce the risk of gynecological cancers in Lynch syndrome. J Engl J Med 2006; 354:261–9.CrossRefGoogle ScholarPubMed

Kwon, JS, Sun, CC, Peterson, SK, et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndromes. Cancer 2008; 113:326–35.CrossRefGoogle Scholar

Wennstrom, J, Pierce, ER, McKusick, VA. Hereditary benign and malignant lesions of the large bowel. Cancer 1974; 34:850.3.0.CO;2-S>CrossRefGoogle ScholarPubMed

American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121:195.CrossRefGoogle Scholar

Van Lier, MG, Wagner, A, Mathus-Vliegen, EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105:1258.CrossRefGoogle ScholarPubMed

Giardiello, FM, Brensinger, JD, Tersmette, AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447.CrossRefGoogle ScholarPubMed